Back

The effect of kidney dysfunction on introducing guideline-derived medical therapy and on mortality among hospitalized patients with heart failure with reduced ejection fraction

29 August 2022 (11:15 - 12:00)
Organised by:
Congress Presentation Part of: Chronic heart failure - The kidney and heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Balazs Muk

Gottsegen National Cardiovascular Center, Budapest (Hungary)

7 More presentations in this session

Presentation thumbnail
Predicting the long-termoutcome of patients admitted with acute heart failure to the emergency department using renal markers
Doctor J. Borges-Rosa (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Prognostic value of estimating appendicular muscle mass in heart failure using creatinine/cystatin C
Doctor T. Sunayama (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Clinical impact of chronic kidney disease on appendicular skeletal muscle mass and mortality in hospitalized patients with acute heart failure
Mr E. Akiyama (Saitama, JP)
Abstract Slides
Presentation thumbnail
Causes of death in patients with chronic kidney disease: Insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
Professor A. Singh (Boston, US)
Abstract Slides
Presentation thumbnail
Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: Insights from PARADIGM-HF
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - The kidney and heart failure

The Event

Event poster

ESC Congress 2022

29 August 2022 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Optimization and long-term applicability of guideline-directed medical therapy based on kidney dysfunction after heart failure hospitalization: how are mortality and rehospitalization rates affected?
22 May 2023
thumbnail
Congress Presentation
The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?
30 June 2021
thumbnail
Congress Presentation
Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i
31 August 2024
thumbnail
Congress Session
Chronic kidney disease and heart failure
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources